Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Buy" by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $43.00.

Several equities research analysts have issued reports on the stock. Stifel Nicolaus started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price objective for the company. TD Cowen assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating for the company. Rodman & Renshaw started coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price objective on the stock. HC Wainwright began coverage on Bicara Therapeutics in a research report on Friday, December 6th. They set a "buy" rating and a $42.00 price objective on the stock. Finally, Morgan Stanley started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price for the company.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently bought and sold shares of BCAX. Cinctive Capital Management LP bought a new stake in shares of Bicara Therapeutics during the 3rd quarter worth approximately $229,000. Barclays PLC acquired a new position in Bicara Therapeutics during the third quarter valued at approximately $255,000. Jane Street Group LLC bought a new stake in Bicara Therapeutics during the third quarter worth $309,000. Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics during the third quarter worth $358,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $462,000.

Bicara Therapeutics Price Performance

Bicara Therapeutics stock remained flat at $19.12 during mid-day trading on Thursday. The company's stock had a trading volume of 250,199 shares, compared to its average volume of 425,333. The stock's fifty day simple moving average is $20.75. Bicara Therapeutics has a fifty-two week low of $16.01 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). As a group, sell-side analysts expect that Bicara Therapeutics will post -2.59 EPS for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.